Fan Zhiwen, Sun Xinyue, Chen Xuelian, Liu Huimin, Miao Xiulian, Guo Yan, Xu Yong, Li Jie, Zou Xiaoping, Li Zilong
Department of Pathology, Nanjing Drum Tower Hospital Affiliated with Nanjing University School of Medicine, Nanjing, China.
State Key Laboratory of Natural Medicines, Department of Pharmacology, China Pharmaceutical University, Nanjing, China.
JHEP Rep. 2023 May 26;5(9):100805. doi: 10.1016/j.jhepr.2023.100805. eCollection 2023 Sep.
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is characterised by accelerated lipid deposition, aberrant inflammation, and excessive extracellular matrix production in the liver. Short of effective intervention, NAFLD can progress to cirrhosis and hepatocellular carcinoma. In the present study we investigated the involvement of the C-C motif ligand 11 (CCL11) in NAFLD pathogenesis.
NAFLD was induced by feeding mice with a high-fat high-carbohydrate diet. CCL11 targeting was achieved by genetic deletion or pharmaceutical inhibition. The transcriptome was analysed using RNA-seq.
We report that CCL11 expression was activated at the transcription level by free fatty acids (palmitate) in hepatocytes. CCL11 knockdown attenuated whereas CCL11 treatment directly promoted production of pro-inflammatory/pro-lipogenic mediators in hepatocytes. Compared with wild-type littermates, CCL11 knockout mice displayed an ameliorated phenotype of NAFLD when fed a high-fat high-carbohydrate diet as evidenced by decelerated body weight gain, improved insulin sensitivity, dampened lipid accumulation, reduced immune cell infiltration, and weakened liver fibrosis. RNA-seq revealed that interferon regulatory factor 1 as a mediator of CCL11 induced changes in hepatocytes. Importantly, CCL11 neutralisation or antagonism mitigated NAFLD pathogenesis in mice. Finally, a positive correlation between CCL11 expression and NAFLD parameters was identified in human patients.
Our data suggest that CCL11 is a novel regulator of NAFLD and can be effectively targeted for NAFLD intervention.
Non-alcoholic fatty liver disease (NAFLD) precedes cirrhosis and hepatocellular carcinoma. In this paper we describe the regulatory role of CCL11, a C-C motif ligand chemokine, in NAFLD pathogenesis. Our data provide novel insights and translational potential for NAFLD intervention.
非酒精性脂肪性肝病(NAFLD)的特征是肝脏中脂质沉积加速、炎症异常以及细胞外基质过度产生。缺乏有效干预的情况下,NAFLD可进展为肝硬化和肝细胞癌。在本研究中,我们调查了C-C基序配体11(CCL11)在NAFLD发病机制中的作用。
通过给小鼠喂食高脂肪高碳水化合物饮食诱导NAFLD。通过基因缺失或药物抑制实现对CCL11的靶向作用。使用RNA测序分析转录组。
我们报告,肝细胞中的游离脂肪酸(棕榈酸)在转录水平激活了CCL11的表达。CCL11基因敲低可减轻肝细胞中促炎/促脂肪生成介质的产生,而CCL11处理则直接促进其产生。与野生型同窝小鼠相比,喂食高脂肪高碳水化合物饮食时,CCL11基因敲除小鼠表现出改善的NAFLD表型,表现为体重增加减缓、胰岛素敏感性提高、脂质积累减少、免疫细胞浸润减轻以及肝纤维化减弱。RNA测序显示,干扰素调节因子1作为CCL11诱导肝细胞变化的介质。重要的是,CCL11中和或拮抗可减轻小鼠NAFLD的发病机制。最后,在人类患者中发现CCL11表达与NAFLD参数之间存在正相关。
我们的数据表明,CCL11是NAFLD的一种新型调节因子,可作为NAFLD干预的有效靶点。
非酒精性脂肪性肝病(NAFLD)先于肝硬化和肝细胞癌出现。在本文中,我们描述了C-C基序配体趋化因子CCL11在NAFLD发病机制中的调节作用。我们的数据为NAFLD干预提供了新的见解和转化潜力。